Oral methotrexate/6-mercaptopurine may Be superior to a multidrug LSA 2L2 maintenance therapy for higher risk childhood acute lymphoblastic leukemia: Results from the NOPHO all-92 study

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 6, 2009, Pages 385-392

  Schmiegelow, Kjeld ^a,c   Heyman, Mats ^d   Kristinsson, Jon ^e   Mogensen, Ulla B ^b   Rosthøj, Susanne ^b   Vettenranta, Kim ^e   Wesenberg, Finn ^e   Saarinen Pihkala, Ulla ^e  

^a Faculty of Medicine   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e Landspitalin Reykjavik ^*

Author keywords

Acute lymphoblastic leukemia; Immune phenotype; Maintenance therapy; Relapse rate

Indexed keywords

ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CELL LINEAGE; CHILD; CHILD CARE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG MEGADOSE; EUROPE; FEMALE; HUMAN; IRRADIATION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SEX RATIO; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DAUNORUBICIN; FEMALE; HUMANS; INFANT; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 67651238887     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181a6e171     Document Type: Article

References (38)

1. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193-2194.
2. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia. 2000;14: 2267-2275.
3. Schmiegelow K, Gustafsson G. Acute Lymphoblastic Leukemia. In: Voute PA BASM, Caron M, eds. Cancer in Children. Oxford: Oxford University Press; 2005: 138-170.
4. Arico M, Baruchel A, Bertrand Y, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia. 2005;19:1145-1152.
5. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12,000 randomised children. Lancet. 1996;347:1783-1788.
6. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomised trials in four consecutive ALL-BFM studies. Hematol Blood Transf. 1990;33:439-450.
7. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508-1516.
8. Schrappe M, Reiter A, Ludwig WD, et al, German-Austrian-Swiss ALL-BFM Study Group. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL- BFM 90. Blood. 2000;95:3310-3322.
9. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia. 2000;14:2286-2294.
10. Eden OB, Harrison G, Richards S, et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia. 2000;14:2307-2320.
11. Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO) (see comments). Acta Paediatr. 1998;87:1151-1161.
12. Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer. 1998;82:600-612.
13. Saarinen-Pihkala UM, Gustafsson G, Carlsen N, et al. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL) : nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer. 2004;42:8-23.
14. Saarinen-Pihkala UM, Lanning M, Perkkio M, et al. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol. 2000;34:319-327.
15. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc (B). 1972;34:187-220.
16. Andersen PK, Borgan Ø, et al. Statistical Models Based on Counting Processes. New York: Springer-Verlag; 1993.
17. Siegel S, Castellan NJ. Nonparametric statistics for the Behavioral Sciences. Singapore: McGrawHill; 1988.
18. Kaplan EJ, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo Ther. 1966;50:163-170.
20. Zuna J, Ford AM, Peham M, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2004;10:5355-5360.
21. Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet. 1991;338: 1315-1318.
22. Kumagai M, Manabe A, Pui CH, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest. 1996;97:755-760.
23. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76:907-912.
24. Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry. 1997;36:2501-2506.
25. Lin TL, Vala MS, Barber JP, et al. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007;21:1915-1920.
26. Mudry RE, Fortney JE, York T, et al. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 2000;96:1926-1932.
27. Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol. 2003;31:693-701.
28. Keyhani A, Jendiroba DB, Freireich EJ. Angiogenesis and leukemia. Leuk Res. 2001;25:639-645.
29. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-821.
30. Kamen BA, Glod J, Cole PD. Metronomic therapy from a pharmacologist's view. J Pediatr Hematol Oncol. 2006;28: 325-327.
31. Miller DR, Leikin SL, Albo VC, et al. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol. 1989;7:316-325.
32. Anonymous. Duration of chemotherapy in childhood acute lymphoblastic leukaemia. The medical research council's working party on leukaemia in childhood. Med Pediatr Oncol. 1982;10:511-520.
33. Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1991;8:301-312.
34. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817-2823.
35. Schmiegelow K, Pulczynska MK. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol. 1990;12:462-467.
36. Schmiegelow K, Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer. 1990;61:767-772.
37. Schmiegelow K, Schroder H, Gustafsson G, et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol. 1995;13:345-351.
38. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 1994;343:1188-1190.